Page 11 - 南京医科大学学报自然科学版
P. 11
第43卷第5期 花私齐,华子春. 细菌疗法在肿瘤临床治疗中的进展及应用[J].
2023年5月 南京医科大学学报(自然科学版),2023,43(5):589-594 ·593 ·
(6369):1443-1448 therapies for cancer treatment[J]. Semin Cancer Biol,
[4] FU A,YAO B,DONG T,et al. Tumor⁃resident intracellu⁃ 2022,86(Pt 2):1163-1178
lar microbiota promotes metastatic colonization in breast [17] RADOSHEVICH L,COSSART P. Listeria monocytogenes:
cancer[J]. Cell,2022,185(8):1356-1372 towards a complete picture of its physiology and pathogen⁃
[5] GELLER L T,BARZILY⁃ROKNI M,DANINO T,et al. Po⁃ esis[J]. Nat Rev Microbiol,2018,16(1):32-46
tential role of intratumor bacteria in mediating tumor re⁃ [18] OLADEJO M,PATERSON Y,WOOD L M. Clinical expe⁃
sistance to the chemotherapeutic drug gemcitabine[J]. rience and recent advances in the development of listeria⁃
Science,2017,357(6356):1156-1160 based tumor immunotherapies[J]. Front Immunol,2021,
[6] ROSENTHAL S R. BCG vaccination against tuberculosis (12):642316
[J]. Am Rev Respir Dis,1983,128(4):776 [19] LE D T,WANG⁃GILLAM A,PICOZZI V,et al. Safety and
[7] PEARL R. On the pathological relations between cancer survival with GVAX pancreas prime and listeria monocy⁃
and tuberculosis[J]. Exp Biol Med,1928,26(1):73-75 togenes⁃expressing mesothelin(CRS⁃207)boost vaccines
[8] LANGE C,AABY P,BEHR M A,et al. 100 years of My⁃ for metastatic pancreatic cancer[J]. J Clin Oncol,2015,
cobacterium bovis bacille Calmette⁃Guérin[J]. Lancet In⁃ 33(12):1325-1333
fect Dis,2022,22(1):e2-e12 [20] HASSAN R,ALLEY E,KINDLER H,et al. Clinical re⁃
[9] RENTSCH C A,BOSSHARD P,MAYOR G,et al. Results sponse of live⁃attenuated,listeria monocytogenes express⁃
of the phase I open label clinical trial SAKK 06/14 assess⁃ ing mesothelin(CRS⁃207)with chemotherapy in patients
ing safety of intravesical instillation of VPM1002BC,a re⁃ with malignant pleural mesothelioma[J]. Clin Cancer
combinant mycobacterium bacillus calmette guerin Res,2019,25(19):5787-5798
(BCG),in patients with non⁃muscle invasive bladder can⁃ [21] BASU P,MEHTA A,JAIN M,et al. A randomized phase
cer and previous failure of conventional BCG therapy[J]. 2 study of ADXS11⁃001 listeria monocytogenes⁃listerioly⁃
Oncoimmunology,2020,9(1):1748981 sin O immunotherapy with or without cisplatin in treat⁃
[10] RENTSCH C A,THALMANN G N,LUCCA I,et al. A ment of advanced cervical cancer[J]. Int J Gynecol Can⁃
phase 1/2 single⁃arm clinical trial of recombinant bacillus cer,2018,28(4):764-772
calmette ⁃ guerin(BCG)VPM1002BC immunotherapy in [22] PANGILINAN C R,WU L H,LEE C H. Salmonella im⁃
non⁃muscle⁃invasive bladder cancer recurrence after con⁃ pacts tumor⁃induced macrophage polarization,and inhib⁃
ventional BCG therapy:SAKK 06/14[J]. Eur Urol Oncol, its SNAI1⁃mediated metastasis in melanoma[J]. Cancers
2022,5(2):195-202 (Basel),2021,13(12):2894
[11] ROSSER C J,TIKHONENKOV S,NIX J W,et al. Safety, [23] MURAKAMI T,HIROSHIMA Y,MIYAKE K,et al. Effi⁃
tolerability,and long⁃term clinical outcomes of an IL⁃15 cacy of tumor ⁃ targeting salmonella typhimurium A1 ⁃ R
analogue(N⁃803)admixed with bacillus calmette⁃guerin against malignancies in patient⁃derived orthotopic xeno⁃
(BCG)for the treatment of bladder cancer[J]. Oncoimmu⁃ graft(PDOX)murine models[J]. Cells,2019,8(6):599
nology,2021,10(1):1912885 [24] MI Z,FENG Z C,LI C,et al. Salmonella⁃mediated cancer
[12] JIANG X,WANG J,DENG X,et al. Role of the tumor mi⁃ therapy:an innovative therapeutic strategy[J]. J Cancer,
croenvironment in PD⁃L1/PD⁃1⁃mediated tumor immune 2019,10(20):4765-4776
escape[J]. Mol Cancer,2019,18(1):10 [25] LOW K B,ITTENSOHN M,LUO X,et al. Construction of
[13] 任筱寒,王尚乾,秦 超. 免疫检查点抑制剂在泌尿系 VNP20009:a novel,genetically stable antibiotic⁃sensitive
统恶性肿瘤中的应用[J]. 南京医科大学学报(自然科 strain of tumor⁃targeting Salmonella for parenteral admin⁃
学版),2021,41(1):141-148 istration in humans[J]. Methods Mol Med,2004,(90):
[14] BALAR A V,KAMAT A M,KULKARNI G S,et al. Pem⁃ 47-60
brolizumab monotherapy for the treatment of high⁃risk non⁃ [26] TOSO J F,GILL V J,HWU P,et al. Phase I study of the
muscle ⁃ invasive bladder cancer unresponsive to BCG intravenous administration of attenuated Salmonella ty⁃
(KEYNOTE⁃057):an open⁃label,single⁃arm,multicentre, phimurium to patients with metastatic melanoma[J]. J
phase 2 study[J]. Lancet Oncol,2021,22(7):919-930 Clin Oncol,2002,20(1):142-152
[15] D’ORAZIO S E F. Innate and adaptive immune respons⁃ [27] NEMUNAITIS. J,CUNNINGHAM. C,SENZER. N,et al.
es during listeria monocytogenes infection[J/OL]. Micro⁃ Pilot trial of genetically modified,attenuated Salmonella
biol Spectr,2019,7(3)[2023⁃02⁃01],DOI:10.1128/mi⁃ expressing the E. coli cytosine deaminase gene in refracto⁃
crobiolspec.GPP3⁃0065-2019 ry cancer patients[J]. Cancer Gene Ther,2003,10(10):
[16] HOWELL L M,FORBES N S. Bacteria ⁃ based immune 737-744